Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary... see more

Recent & Breaking News (NDAQ:FBIO)

Avenue Therapeutics Announces Reverse Stock Split

GlobeNewswire 16 hours ago

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire March 28, 2024

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

GlobeNewswire March 28, 2024

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

GlobeNewswire March 25, 2024

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire March 22, 2024

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire March 21, 2024

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire March 18, 2024

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

GlobeNewswire March 18, 2024

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

GlobeNewswire March 18, 2024

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

GlobeNewswire March 15, 2024

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

GlobeNewswire March 15, 2024

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

GlobeNewswire March 13, 2024

Fortress Biotech to Participate in 36th Annual ROTH Conference

GlobeNewswire March 12, 2024

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

GlobeNewswire March 11, 2024

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

GlobeNewswire March 11, 2024

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

GlobeNewswire March 7, 2024

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

GlobeNewswire March 4, 2024

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

GlobeNewswire February 22, 2024

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

TheNewsWire February 2, 2024

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

GlobeNewswire January 29, 2024